ArticleOdontology2026
Rosuvastatin-loaded collagen membrane in grade II mandibular furcation defects in periodontal disease: a split-mouth randomized controlled trial.
Article in Odontology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Periodontal disease is a chronic infectious disease that adversely affects human oral health and overall wellbeing, with furcation involvement posing a significant therapeutic challenge. Rosuvastatin, a hydrophilic statin widely used in medicine, has demonstrated pleiotropic properties including anti-inflammatory and osteogenic effects, making it a promising adjunct for periodontal regeneration. This study aimed to assess the efficacy of a 1.2% rosuvastatin-loaded collagen membrane in the treatment of grade II mandibular furcation defects. A split-mouth randomized controlled trial was conducted on 15 systemically healthy patients presenting with bilateral Grade II mandibular furcation defects (30 defects in total). Control sites received bone graft and collagen membrane, while test sites were treated with bone graft and a 1.2% rosuvastatin-loaded collagen membrane. Clinical parameters including probing depth (PD), clinical attachment level (CAL), radiographic defect depth (DD), and alkaline phosphatase (ALP) levels in gingival crevicular fluid (GCF) were recorded at baseline, 3 months, and 6 months postoperatively. At 6 months, both groups showed significant improvements in PD, CAL, DD, and ALP levels. The control group had PD 4.5 ± 0.9 mm, CAL 5.7 ± 1.1 mm, DD 3.5 ± 0.3 mm, and ALP 189.5 ± 13.2 pg/mL, while the test group showed PD 3.0 ± 0.7 mm, CAL 4.0 ± 1.0 mm, DD 2.5 ± 0.3 mm, and ALP 204.3 ± 12.7 pg/mL, indicating superior outcomes with rosuvastatin (p < 0.05). The application of a 1.2% rosuvastatin-loaded collagen membrane resulted in significantly greater improvements in clinical, radiographic, and biochemical parameters compared with the control treatment in Grade II mandibular furcation defects.
Indexed as
Identifiers
42380701What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.